Cencora (COR) continues to make considerable strides in the biotech sector, consistently beating earnings estimates with impressive gains seen over the past five years. A recent internal sell-off of shares raised concerns, but the company remains undervalued with significant growth potential, risk notwithstanding.
ProVise Management Group LLC and
Swiss National Bank are investing in Cencora, showing market confidence. Struggles were encountered with Walgreens and data breaches, but Cencora's earnings and revenues continue to surpass estimates.
CEO Steven Collis has made headlines selling his shares, but the stock holds strong.
Insider trading practices are under scrutiny but haven't deterred investment. Despite certain timidity in its outlook due to data breach concerns and ambiguous valuations, experts suggest it is a top value stock for long-term growth. Cencora's robust growth is further evidenced by significant investments from
BNP Paribas Asset Management and
LSV Asset Management.
Q3 and Q2 earnings reflect strong performance and are eagerly anticipated.
Janney Montgomery Scott LLC and
Sei Investments Co. recently acquired new positions, while
First Trust Direct Indexing L.P. and
Quantbot Technologies LP add to their existing stake.
Cencora COR News Analytics from Wed, 30 Aug 2023 07:00:00 GMT to Sat, 20 Jul 2024 15:01:49 GMT -
Rating 8
- Innovation 5
- Information 9
- Rumor -2
